ADXS - アドバクシス （Advaxis Inc.）ADXSのニュース
Advaxis, Inc. (ADXS: OTCQX U.S.) | Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee 2023/03/03 13:00:35 OTC Markets
Advaxis GAAP EPS of -$8.46, revenue of $0.25M 2023/02/10 12:45:35 Seeking Alpha
Advaxis press release (ADXS): FY GAAP EPS of -$8.46.Revenue of $0.25M, compared with $3.2M for the fiscal year 2021.Cash position On October 31, 2022, the consolidated cash and…
Advaxis and Ayala Pharmaceuticals Complete Merger 2023/01/19 14:37:00 Advaxis
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J. , Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes
Ayala sees last day of trading as merger with Advaxis takes place 2023/01/18 19:24:32 Seeking Alpha
Ayala Pharmaceuticals'' (AYLA) last day of trading is at market close Wednesday as the company''s merger with Advaxis (ADXS) takes place.
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 2023/01/12 13:04:00 businessfortnight.com
Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reportedFour out of […] The post Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 appeared first on Businessfortnight .
Advaxis GAAP EPS of -$1.90, revenue of $0.25M 2022/06/08 12:07:36 Seeking Alpha
Advaxis press release (ADXS): Q2 GAAP EPS of -$1.90.Revenue of $0.25M (-81.8% Y/Y).As of April 30, 2022, the Company had approximately $32.1 million in cash and cash equivalents.
Advaxis (ADXS) Investor Presentation - Slideshow (OTCMKTS:ADXS) 2022/06/04 15:33:36 Seeking Alpha
The following slide deck was published by Advaxis, Inc.
Advaxis to implement one-for-80 reverse split 2022/06/03 20:38:54 Seeking Alpha
Advaxis <> to implement a one-for-80 reverse split of its issued and outstanding common stock
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology 2022/05/26 21:00:00 Advaxis
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® ( pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting 2022/05/26 21:00:00 ForexTV
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA® (pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503 being dosed in combination with KEYTRUDA® … The post Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting appeared first on ForexTV .
Advaxis GAAP EPS of -$1.90, revenue of $0.25M 2022/06/08 12:07:36 Seeking Alpha
Advaxis press release (ADXS): Q2 GAAP EPS of -$1.90.Revenue of $0.25M (-81.8% Y/Y).As of April 30, 2022, the Company had approximately $32.1 million in cash and cash equivalents.
Advaxis (ADXS) Investor Presentation - Slideshow (OTCMKTS:ADXS) 2022/06/04 15:33:36 Seeking Alpha
The following slide deck was published by Advaxis, Inc.
Advaxis to implement one-for-80 reverse split 2022/06/03 20:38:54 Seeking Alpha
Advaxis <> to implement a one-for-80 reverse split of its issued and outstanding common stock
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology 2022/05/26 21:00:00 Advaxis
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® ( pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting 2022/05/26 21:00:00 ForexTV
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA® (pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503 being dosed in combination with KEYTRUDA® … The post Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting appeared first on ForexTV .